Publications by authors named "J L Cazin"
Article Synopsis
- * ADCs combine antibodies with cytotoxics for targeted cancer therapy and are showing promise in metastatic breast and bladder cancers, with examples like trastuzumab deruxtecan for HER2-positive breast cancer.
- * Bispecific antibodies can engage both tumor and immune cells, facilitating immune responses against cancer, with several candidates in development for conditions like lymphoma and myeloma.
Article Synopsis
- The COVID-19 pandemic has significantly affected health care for cancer patients, who are particularly vulnerable to severe complications from the virus, prompting oncologists to reassess their treatment approaches.
- This review discusses international guidelines that aim to optimize cancer care by proposing alternative treatment options that reduce the need for hospital visits, especially for immunocompromised patients.
- It also highlights the challenges related to drug interactions and adverse effects due to polypharmacy in cancer patients and presents a data board to help healthcare professionals manage drug-related issues effectively during this pandemic period.
There is currently a paucity of data on salvage intracerebrospinal fluid (intra-CSF) chemotherapy in leptomeningeal metastases (LM). This report is a single-institution experience with salvage treatment in patients with breast cancer (BC) and LM. This retrospective cohort describes 24 consecutive patients with BC selected for a second-line of treatment for LM.
View Article and Find Full Text PDFBackground/aim: Prolonged overall survival (OS) has been reported for selected patients with leptomeningeal metastases (LM). The management and treatment of such patients is poorly-described. We report our experience on breast cancer (BC)-associated LM and patients with prolonged survival.
View Article and Find Full Text PDFApproximately 2-5 % of patients with breast cancer (BC) develop leptomeningeal metastasis (LM). 103 consecutive patients with BC were diagnosed with LM and initially treated with intra-CSF liposomal cytarabine from 2007 to 2011 at a single institution. Correlations were determined with respect to patient characteristics and BC subtype with regard to overall survival (OS).
View Article and Find Full Text PDF